Welcome to our dedicated page for TNF Pharmaceuticals news (Ticker: TNFA), a resource for investors and traders seeking the latest updates and insights on TNF Pharmaceuticals stock.
The TNFA news archive on Stock Titan captures the transition of TNF Pharmaceuticals, Inc. from a clinical stage biopharmaceutical company into Q/C Technologies, Inc., a business focused on quantum-class photonic computing and blockchain infrastructure. While the stock now trades on Nasdaq under the ticker QCLS, historical news under the TNFA symbol documents the company’s evolution in strategy, financing and regulatory status.
Earlier news releases describe TNF Pharmaceuticals as a clinical stage pharmaceutical company committed to extending healthy lifespan through two drug platforms: isomyosamine, a small molecule TNF-α modulator for inflammatory and autoimmune conditions, and Supera-CBD, a synthetic cannabidiol derivative being developed for chronic pain, addiction and epilepsy. Coverage includes updates on collaborations such as a philanthropic partnership with the DADA2 Foundation for a Compassionate Use study of isomyosamine in a rare pediatric autoinflammatory disease, as well as references to work with Renova on GLP-induced inflammation and muscle damage.
Subsequent articles highlight a major strategic shift. TNF Pharmaceuticals announced a licensing agreement for LightSolver Ltd.’s laser-based processing unit (LPU) technology, obtaining exclusive rights for cryptocurrency and blockchain applications. News items explain how this light-based, quantum-inspired computing platform is designed to solve compute-intensive problems at the speed of light and reduce energy consumption in crypto infrastructure. Additional releases cover the company’s decision to change its corporate name to Q/C Technologies, adopt the new Nasdaq ticker QCLS, and position itself as a pioneer in energy-efficient quantum class, high-performance computing infrastructure.
Investors and researchers can use this page to review TNFA-related news on clinical development updates, philanthropic collaborations, reverse stock split and Nasdaq compliance actions, private placement financings, the acquisition of LPU Holdings LLC, and the formal name and ticker changes. Together, these items provide a detailed narrative of how the TNFA entity evolved into Q/C Technologies and reoriented its focus toward photonic computing and blockchain infrastructure.
TNF Pharmaceuticals, formerly MyMD Pharmaceuticals, has begun trading under its new Nasdaq stock symbol TNFA as of July 24, 2024. This change reflects the company's focus on inhibiting TNF-alpha to regulate the immuno-metabolic system. The company's lead clinical candidate, MYMD-1, blocks excess TNF-α activity, potentially restoring immune system control and regulation.
Dr. Mitchell Glass, President and Chief Medical Officer, emphasized that this rebranding aligns with their core science and highlights MYMD-1's potential as the first TNF-α inhibitor in its indication. The company's CUSIP remains unchanged, and current stockholders need not take any action regarding the symbol change.